金格伦A通过调节TLR4/MyD88/NF-κB通路来改善呼吸道炎症和喘中的重塑
Yingjie Zhu1, Lin Chen2, Jiajia Lin2
1Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, 362000, China; Fujian Key Laboratory of Lung Stem Cells, Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian, China; Fujian Provincial Clinical Research Center of Interventional Respirology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, 362000, China.
丁格伦A (GA) 通过抑制TLR4/MyD88/NF-κB通路,有效地减少呼吸道炎症和喘中的重塑. 这项研究为使用GA作为喘治疗新型治疗剂提供了坚实的基础.
科学领域:
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
背景情况:
- 喘涉及持续的呼吸道炎症和重塑,表皮-介质细胞过渡 (EMT) 是一个关键机制.
- 生A (GA) 是一种生衍生化合物,具有抗炎和抗氧化特性,但其在喘中的作用尚未被探索.
研究的目的:
- 为了研究GA对呼吸道炎症和喘重塑的抑制作用.
- 阐明GA在喘中的作用的潜在分子机制.
主要方法:
- 在体外研究中使用MLE-12细胞来评估炎症性细胞因子分泌,EMT标记物和NF-κB通路,通过RT-qPCR,西斑和免疫光.
- 在体内研究涉及喘小鼠模型,采用组织学染色 (H&E,马森三色素,PAS) 和分子技术 (西斑,免疫光,免疫组织化学) 来评估呼吸道病理和信号通路.
- 使用分子对接,TLR4过度表达和DARTS测试来确认GA的作用机制,特别是其与TLR4的相互作用.
主要成果:
- 在体外,GA抑制了室内灰尘 (HDM) 诱导的炎症因素和EMT,并在喘小鼠中抑制了气道炎症,细胞因子分泌和EMT相关的重塑.
- GA的治疗效果与核β-catenin和TLR4/MyD88/NF-κB信号级联的抑制有关.
- 分子对接表明GA与TLR4,MyD88和TRAF6结合;GA治疗显著抑制了TLR4通路,在TLR4过度表达细胞中效应逆转.
结论:
- 通过抑制TLR4/MyD88/NF-κB信号通路,GA在喘中显示出显著的抗炎和抗重塑作用.
- 这些发现支持GA作为喘管理的有希望的治疗候选者,提供了一种新的治疗策略.
更多相关视频
10:39Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
Published on: April 16, 2019
08:44Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
Published on: May 30, 2020
相关概念视频
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
